270. Chronic recurrent multifocal osteomyelitis Clinical trials / Disease details
Clinical trial : 1 / Drugs : 10 - (DrugBank : 9) / Drug target genes : 6 - Drug target pathways : 73
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04725422 (ClinicalTrials.gov) | August 1, 2018 | 18/1/2021 | CHronic Nonbacterial Osteomyelitis International Registry (CHOIR) | CHronic Nonbacterial Osteomyelitis International Registry (CHOIR) | Chronic Nonbacterial Osteomyelitis;Chronic Recurrent Multifocal Osteomyelitis | Drug: Methotrexate;Drug: Sulfasalazine;Drug: Leflunomide;Drug: Pamidronate;Drug: Zoledronic acid;Drug: Etanercept;Drug: Adalimumab;Drug: Certolizumab;Drug: Infliximab;Drug: Golimumab | Seattle Children's Hospital | Boston Children's Hospital, Boston, MA, USA;Hospital for Special Surgery, New York City, NY, USA;Joseph M Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, USA;Riley Children's Hospital, Indianapolis, IN, USA;University of North Carolina, Chapel Hill, NC, USA;Royal Children's Hospital, Melbourne, Australia;Hacettepe University, Ankara, Turkey;Bambino Gesù Children's Hospital, Rome, Italy;University of British Columbia, Vancouver, BC, Canada;Meyer Children's Hospital, Florence, Italy;Mansoura university, faculty of medicine, Egypt | Recruiting | N/A | 21 Years | All | 2000 | United States |